Form 4: Fulcrum Therapeutics' Chief Medical Officer, Patrick Horn, Acquires 400,000 Stock Options

Patrick Taylor Horn, Chief Medical Officer of Fulcrum Therapeutics, acquired 400,000 stock options on March 18, 2024.

Summary

• On March 18, 2024, Patrick Taylor Horn, the Chief Medical Officer of Fulcrum Therapeutics, Inc., was granted 400,000 stock options.
• The exercise price of these options is $10.12.
• The options vest 25% on the first anniversary of the vesting commencement date of March 18, 2024.
• The remaining shares vest in equal quarterly installments over the following three years, until the fourth anniversary of the vesting commencement date, subject to continued service.
• The options expire on March 17, 2034.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of incentivizing management, but it's not a major market-moving event.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders, incentivizing him to contribute to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The size of the grant is typical for a Chief Medical Officer at a company of Fulcrum Therapeutics' size and stage of development.
• Vesting schedules are also standard, with multi-year vesting periods being common to ensure long-term commitment.

Stakeholder Impact

• The stock option grant could have a slightly positive impact on shareholder sentiment, as it aligns management's interests with those of the shareholders.

Key Dates